Checks on Hologic's Tomo very positive after data, says RBC Capital After conducting checks with radiologists, RBC Capital states that the radiologists were "very impressed" with the results of a study of Hologic's Tomo product. The firm expects about 800 Tomo units to be installed by the end of Hologic's FY13, which is towards the upper end of the company's implied guidance, according to RBC Capital. The firm increased its price target on the shares to $26 from $23 and maintains a Top Pick rating on the stock.
Hologic upgraded to Equal Weight from Underweight at Barclays Barclays analyst Jack Meehan upgraded Hologic to Equal Weight citing improvement in 3D mammography placements. The analyst keeps a $40 price target for shares.